BANK OF AMERICA CORP /DE/ - EVOKE PHARMA INC ownership

EVOKE PHARMA INC's ticker is EVOK and the CUSIP is 30049G104. A total of 22 filers reported holding EVOKE PHARMA INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
BANK OF AMERICA CORP /DE/ ownership history of EVOKE PHARMA INC
ValueSharesWeighting
Q4 2021$048
+269.2%
0.00%
Q2 2021$0
-100.0%
13
-99.8%
0.00%
Q1 2021$12,000
-42.9%
6,200
-25.3%
0.00%
Q4 2020$21,000
+600.0%
8,300
+105.4%
0.00%
Q2 2019$3,000
-62.5%
4,041
+41.9%
0.00%
Q3 2018$8,000
-75.8%
2,848
-71.5%
0.00%
Q3 2017$33,000
+26.9%
10,0000.0%0.00%
Q2 2017$26,000
+23.8%
10,000
+45.5%
0.00%
Q1 2017$21,000
+425.0%
6,875
+266.7%
0.00%
Q4 2016$4,0000.0%1,8750.0%0.00%
Q3 2016$4,000
-80.0%
1,875
-35.1%
0.00%
Q2 2016$20,000
+33.3%
2,887
+0.4%
0.00%
Q1 2016$15,000
+66.7%
2,8750.0%0.00%
Q4 2015$9,000
-83.0%
2,875
-84.3%
0.00%
Q3 2015$53,000
-44.8%
18,2750.0%0.00%
Q2 2015$96,000
-25.6%
18,2750.0%0.00%
Q1 2015$129,000
+41.8%
18,275
+18.7%
0.00%
Q4 2014$91,000
+116.7%
15,400
+100.0%
0.00%
Q3 2014$42,000
-84.5%
7,700
-77.0%
0.00%
Q2 2014$271,000
-3.6%
33,5000.0%0.00%
Q1 2014$281,000
+8.9%
33,500
-3.0%
0.00%
Q4 2013$258,00034,5290.00%
Other shareholders
EVOKE PHARMA INC shareholders Q1 2022
NameSharesValueWeighting ↓
Opaleye Management Inc. 242,500$1,962,0001.69%
SOPHROSYNE CAPITAL LLC 49,000$397,0000.40%
LMR Partners LLP 23,882$187,0000.02%
GEODE CAPITAL MANAGEMENT, LLC 10,276$80,0000.00%
BlackRock Investment Management, LLC 489$4,0000.00%
MORGAN STANLEY 500$4,0000.00%
Tower Research Capital LLC (TRC) 84$1,0000.00%
VANGUARD GROUP INC 48,394$378,0000.00%
UBS AG 727$6,0000.00%
BANK OF AMERICA CORP /DE/ 33,500$271,0000.00%
View complete list of EVOKE PHARMA INC shareholders